Delivery Order SPE2DB24D8003-SPE2DB24FJTKL

Award Date 8/27/24
Potential Completion Date 8/28/24
Potential Value $4.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $9,226.57, is a firm-fixed-price delivery order for the supply of VRAYLAR 4.5 MG CAPSULE 30S, a pharmaceutical product. The contract has an ultimate completion date of March 13, 2025. Dakota Drug, Inc. is a key supplier to the DLA's Troop Support Medical division, providing a range of pharmaceutical and medical products to...
This federal contract award, valued at $8,561.54, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is a firm-fixed price delivery order for the supply of VRAYLAR 3 MG CAPSULE 30S, a pharmaceutical product, to support U.S. Armed Forces medical operations. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which allows the company to provide a comprehensive...
This federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $6,726.07 firm fixed-price delivery order is for the supply of VRAYLAR 1.5 MG CAPSULE 30S, a prescription medication. The contract does not have a set-aside designation. Dakota Drug, Inc. holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA, which allows the company to provide a comprehensive...
This federal contract award was made by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business located in Anoka, Minnesota. The $8,587.02 firm fixed-price delivery order is for the supply of VRAYLAR 3 MG CAPSULE 30S, a pharmaceutical product. The award is not associated with a set-aside program and is scheduled for completion by May 15, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA,...
The U.S. Defense Logistics Agency (DLA) has awarded a Firm Fixed Price Delivery Order contract worth $6,681.60 to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of 4563200640 - VRAYLAR 3 MG CAPSULE 30S. This award is part of the DLA Troop Support Medical's ECAT Generation V Program, a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 held by Dakota Drug, Inc. The contract has an ultimate completion date of January 2, 2024 and does not...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $12,932.87 firm fixed-price contract is for the delivery of VRAYLAR 1.5 MG CAPSULE 30S, a pharmaceutical product, with a performance period through May 6, 2024. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, providing a wide range of pharmaceutical products, medical supplies, and healthcare equipment to support...
This federal contract award, valued at $1,797.26, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract is for the delivery of 4565441401 VRAYLAR 3 MG CAPSULE 30S, a pharmaceutical product, under a firm fixed-price delivery order. Dakota Drug, Inc. holds a significant Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which allows the company to...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of VRAYLAR 1.5 MG CAPSULE 30S, a pharmaceutical product, with a ceiling value of $9,927.91 and a performance period extending to March 11, 2025. The contract was awarded on March 10, 2025 and is a firm fixed-price delivery order contract, without any set-aside designation. Dakota Drug, Inc. is a key supplier for...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of VRAYLAR 3 MG CAPSULE 30S. The firm-fixed-price contract has a ceiling value of $6,191.88 and a period of performance through February 25, 2025. Dakota Drug, Inc. is a key supplier to the DLA, holding a significant single-award Indefinite Delivery Contract (IDC) valued at $999,999,999.00 as part of the DLA Troop Support Medical's ECAT...
This federal contract award, identified as SPE2DX15D8001|SPE2DX24FBQWZ, was issued by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $17,018.46, is a firm fixed-price delivery order for the supply of VRAYLAR 3 MG CAPSULE 30S, a pharmaceutical product. Dakota Drug, Inc. is a key supplier to the DLA, holding a significant single-award Indefinite Delivery Contract (IDC) valued at...
  • SPE2DB24D8003
    Indefinite Delivery Contract
  • SPE2DB24D8003-SPE2DB24FJTKL
    Delivery Order

This federal contract award, valued at $4,508.95, was issued by the Defense Logistics Agency (DLA) to prime contractor Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract is for the delivery of VRAYLAR 1.5 MG CAPSULE 30S, a pharmaceutical product, with a completion date of August 28, 2024.

Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, valued at $999,999,999.00, which allows the company to provide a comprehensive range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations. This specific award is structured as a firm fixed-price delivery order and does not have a set-aside designation.

Generated 11/26/24, 9:02 AM